12.00
+0.78(+6.95%)
Currency In USD
| Previous Close | 11.22 |
| Open | 11.36 |
| Day High | 12.33 |
| Day Low | 11.4 |
| 52-Week High | 18.2 |
| 52-Week Low | 9.24 |
| Volume | 3.96M |
| Average Volume | 1.57M |
| Market Cap | 3.75B |
| PE | 0 |
| EPS | 0 |
| Moving Average 50 Days | 10.29 |
| Moving Average 200 Days | 10.64 |
| Change | 0.78 |
Data not available
Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
GlobeNewswire Inc.
May 08, 2025 8:17 PM GMT
RESEARCH TRIANGLE PARK, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2025 financial
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025
GlobeNewswire Inc.
Mar 06, 2025 9:22 PM GMT
RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quart
Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany
GlobeNewswire Inc.
Feb 07, 2025 12:00 PM GMT
~ PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to <18 Years of Age with Localized, Non-Metastatic Solid Tumors ~ ~ Norgin